Apatinib Plus Etoposide Versus Etoposide Alone for Platinum-resistant Recurrent Ovarian Cancer

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2017
It is a prospective multi-center trial, platinum-resistant ovarian cancer patients will be randomized in two groups, one group will be treated with Apatinib plus Etoposide, the other will be treated with Etoposide alone. It is aimed to see the efficacy and safety of Apatinib plus Etoposide for the platinum-resistant ovarian cancer patients
Epistemonikos ID: da73ce8883c8ecc6a4cc083ace3bca35ea4101ea
First added on: May 21, 2024